We focused the analysis to NSCLC and melanoma since these indications have the most comprehensive data of anti-PD-(L)1 therapies (due to early approval years and first line indication) and, therefore, the results might not be generalizable to other tumor types. This evidence concerns the gene CD274 and melanoma.